415 related articles for article (PubMed ID: 18019783)
41. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
[TBL] [Abstract][Full Text] [Related]
42. [Value of combination therapy in treatment of hypertension].
Kreutz R
Krankenpfl J; 2005; 43(7-10):255. PubMed ID: 16515324
[No Abstract] [Full Text] [Related]
43. First-line treatment of hypertension: from monotherapy to fixed low-dose combination therapy.
Piot O; Gallois H; Baguet JP; Mallion JM
J Hum Hypertens; 2001 Jul; 15(7):443-6. PubMed ID: 11464252
[No Abstract] [Full Text] [Related]
44. Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy.
Hong SH; Wang J; Tang J
Am J Hypertens; 2013 Jul; 26(7):879-87. PubMed ID: 23512697
[TBL] [Abstract][Full Text] [Related]
45. [Antihypertensive therapy: the end of the flag pole?].
Unger T
Fortschr Med; 1997 Sep; 115(26):55-7. PubMed ID: 9417414
[No Abstract] [Full Text] [Related]
46. [The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension].
Widimský J
Vnitr Lek; 2009 Feb; 55(2):123-30. PubMed ID: 19348394
[TBL] [Abstract][Full Text] [Related]
47. Doxazosin in the current treatment of hypertension.
Wykretowicz A; Guzik P; Wysocki H
Expert Opin Pharmacother; 2008 Mar; 9(4):625-33. PubMed ID: 18312163
[TBL] [Abstract][Full Text] [Related]
48. Combination agents as a means of improving adherence and other aspects of the sixth Joint National Committee Report.
Basile JN
South Med J; 2000 May; 93(5):534-6. PubMed ID: 10832960
[No Abstract] [Full Text] [Related]
49. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
White WB
Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension.
Martinez A; Sanchez M
Expert Opin Pharmacother; 2008 Jan; 9(1):137-43. PubMed ID: 18076345
[TBL] [Abstract][Full Text] [Related]
51. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
Chapman N; Chang CL; Dahlöf B; Sever PS; Wedel H; Poulter NR;
Circulation; 2008 Jul; 118(1):42-8. PubMed ID: 18559700
[TBL] [Abstract][Full Text] [Related]
52. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
53. Single-pill combination of amlodipine and valsartan in the management of hypertension.
Flack JM; Hilkert R
Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
[TBL] [Abstract][Full Text] [Related]
54. Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system.
Guzik P; Wykretowicz A; Krauze T; Piskorski J; Adamska K; Milewska A; Wesseling KH; Wysocki H
Hypertens Res; 2008 Mar; 31(3):443-53. PubMed ID: 18497463
[TBL] [Abstract][Full Text] [Related]
55. ACE inhibitor-based treatment and antihypertensive effects in patients with type 2 diabetes.
Jarmuzewska EA; Rocchi R; Guidoni A; Mangoni AA
Panminerva Med; 2008 Sep; 50(3):207-16. PubMed ID: 18927524
[TBL] [Abstract][Full Text] [Related]
56. [Therapeutic options--fixed dose combinations for treatment of hypertension. Report of the 3rd annual meeting of the American Society of Hypertension, New York, 1988].
Fortschr Med Suppl; 1989; 76():1-15. PubMed ID: 2635682
[No Abstract] [Full Text] [Related]
57. Benefits and risks of combination therapy in hypertension.
Node K
Hypertens Res; 2009 Sep; 32(9):727-8. PubMed ID: 19609269
[No Abstract] [Full Text] [Related]
58. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
59. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
60. The use of free and fixed drug combinations to improve hypertension control in our populations.
Chalmers J
Eur Heart J; 1999 Aug; 20(15):1060-1. PubMed ID: 10413632
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
